Abstract
The anti-CD52 (Campath-1) monoclonal antibodies (Mabs) have a substantial history of use for controlling graft-versus-host disease in allogeneic bone marrow transplantation. Now, with the availability of a humanised form, alemtuzumab (Campath-1H), and the demonstration that this agent can reduce the tumour burden in B-CLL, a new niche may be found – as a potentially curative agent in which its tumour purging ability in vivo combines with its role as a conditioning agent in nonmyeloablative transplantation. Review of the literature shows that alemtuzumab has unique advantages as a method of depleting malignant lymphocytes, including those in patients resistant to conventional chemotherapy. Alemtuzumab can also be used in BMT for depletion of normal T and B lymphocytes of both the recipient and donor for prevention of graft rejection and GVHD. It allows good stem cell recovery with resultant rapid engraftment, has a low risk of EBV-triggered secondary malignancy and does not interfere with blood stem cell mobilisation. As a method of eliminating the malignant clone in B-CLL, alemtuzumab has shown remarkable efficacy in heavily pre-treated patients, a number of whom have progressed to autologous or allogeneic transplantation. Efficacy data are shown within the context of other transplantation data for B-CLL. These results indicate that the combination of tumour-depleting and immunosuppressive properties of alemtuzumab should be explored, with the hope of providing improved treatment options for elderly patients with advanced B-CLL or indolent lymphoma whose prognosis is too poor currently to allow treatment with traditional regimens of high-dose myeloablative chemotherapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Weiden PL, Sullivan KM, Fluornoy N et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation New Engl J Med 1981 304: 1529 1533
Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation Blood 1990 75: 555 562
Waldmann H, Polliak A, Hale G et al. Elimination of graft-versus-host disease by in vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1) Lancet 1984 2: 483 486
Slavin S, Waldmann H, Or R et al. Prevention of graft-vs-host disease in allogeneic transplantation for leukemia by T-cell depletion in vitro prior to transplantation Transplant Proc 1985 17: 465 467
Cobbold SP, Martin G, Qin S, Waldmann H . Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance Nature 1986 323: 164 166
Hale G, Waldmann H . Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases Bone Marrow Transplant 1994 13: 597 611
Slavin S, Strober S, Fuks Z, Kaplan HS . Long-term survival of skin allografts in mice treated with fractionated total lymphoid irradiation Science 1976 193: 1252 1254
Slavin S, Naparstek E, Aker M et al. The use of total lymphoid irradiation (TLI) for prevention of rejection of T-lymphocyte depleted bone marrow allografts in non-malignant hematological disorders Transplant Proc 1989 21: 3053 3054
Plunkett W, Saunders PP . Metabolism and action of purine nucleoside analogs Pharmacol Ther 1991 49: 239 268
Williamson L, Wimperis J, Wood M, Woodcock B . Fludarabine treatment and transfusion-associated graft-versus-host disease Lancet 1996 348: 4723
Hale G . The CD52 antigen and development of the CAMPATH antibodies Cytotherapy 2001 3: 137 144
Gilleece MH, Dexter TM . Effect of Campath-1H antibody on human hematopoietic progenitors in vitro Blood 1993 82: 807 812
Riechmann L, Clark M, Waldmann H, Winter G . Reshaping human antibodies for therapy Nature 1988 332: 323 327
Keating MJ, Flinn I, Vinay J et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study Blood 2002 99: 3554 3561
Dearden CE, Matutes E, Cazin B et al. High remission rate in T-cell prolymphocytic leukaemia treated with CAMPATH-1H Blood 2001 98: 1721 1726
Lundin J, Kimby E, Bjorkholm M et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL) Blood 2002 100: 768 773
Kennedy B, Rawstron A, Carter C et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia Blood 2002 99: 2245 2247
Faderl S, Thomas DA, O'Brien S et al. An exploratory study of the combination of monoclonal antibodies CAMPATH-1H and Rituximab in the treatment of CD52 and CD20-positive chronic lymphocytic disorders Blood 2001 98: 365A
Lundin J, Osterborg A, Brittinger G et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas. A phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lympoma J Clin Oncol 1998 16: 3257 3263
Neudorf SM, Rybka W, Ball E et al. The use of counterflow centrifugal elutriation for the depletion of T cells from unrelated donor bone marrow J Hematother 1997 6: 351 359
Cornelissen JJ, Fibbe WE, Schattenberg AV et al. A retrospective Dutch study comparing T cell-depleted allogeneic blood stem cell transplantation vs T cell-depleted allogeneic bone marrow transplantation Bone Marrow Transplant 1998 21: (Suppl. 3) S66 S70
Weiss L, Margel S, Slavin S . Depletion of human lymphocytes from peripheral blood and bone marrow by affinity ligands conjugated to agarose-polyacrolein microsphere beads Appl Biochem Biotechnol 1986 13: 87 96
Frame JN, Collins NH, Cartagena T et al. T cell depletion of human bone marrow. Comparison of Campath-1 plus complement, anti-T cell ricin A chain immunotoxin, and soybean agglutinin alone or in combination with sheep erythrocytes or immunomagnetic beads Transplantation 1989 47: 984 988
Jeong DC, Han CW, Jin JY et al. Effectiveness of rotor off fraction in allogeneic murine bone marrow transplantation with complete disparity of major histocompatibility Exp Hematol 1999 27: 1219 1225
Schattenberg A, Preijers F, Mensink E et al. Survival in first or second remission after lymphocyte-depleted transplantation for Philadelphia chromosome-positive CML in first chronic phase Bone Marrow Transplant 1997 19: 1205 1212
Schaap N, Schattenberg A, Bar B et al. Outcome of transplantation for standard-risk leukaemia with grafts depleted of lymphocytes after conditioning with an intensified regimen Br J Haematol 1997 98: 750 759
O'Donnell PV, Jones RJ, Vogelsang GB et al. CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignancies Bone Marrow Transplant 1998 22: 947 955
Noga SJ, Seber A, Davis JM et al. CD34 augmentation improves allogeneic T cell-depleted bone marrow engraftment J Hematother 1998 7: 151 157
Clarke E, Potter MN, Oakhill A et al. A laboratory comparison of T cell depletion by CD34+ cell immunoaffinity selection and in vitro Campath-1M treatment: clinical implications for bone marrow transplantation and donor leukocyte therapy Bone Marrow Transplant 1997 20: 599 605
Dao MA, Nolta JA . CD34: To select or not to select? That is the question Leukemia 2000 14: 773 776
Zanjani ED, Almeida-Porada G, Livingston AG et al. Human bone marrow CD34− cells engraft in vivo and undergo multilineage expression that includes giving rise to CD34+ cells Exp Hematol 1998 26: 353 360
Zanjani ED, Almeida-Porada G, Livingston AG et al. Engraftment and multilineage expression of human bone marrow CD34− cells in vivo Ann NY Acad Sci 1999 872: 220 222
Hale G, Zhang MJ, Bunjes D et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection Blood 1998 92: 4581 4590
Jacobs P, Wood L, Fullard L et al. T cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease Bone Marrow Transplant 1994 13: 763 769
Hale G, Jacobs P, Wood L et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells Bone Marrow Transplant 2000 26: 69 76
Rebello P, Cwynarski K, Varughese M et al. Phamacokinetics of Campath-1H in bone marrow transplant patients Cytotherapy 2001 3: 261 267
Kottaridis PD, Milligan DW, Chopra R et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation Blood 2000 96: 2419 2425
Curtis RE, Travis LB, Rowlings PA et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study Blood 1999 94: 2208 2216
Hale G, Waldmann H . Risks of developing Epstein–Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH users Blood 1998 91: 3079 3083
Hertenstein B, Hampl W, Bunjes D et al. In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT Bone Marrow Transplant 1995 15: 387 393
Chakrabarti S, Mackinnon S, Chopra R et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of CAMPATH-1H in delaying immune reconstitution but limiting transplant-related mortality Blood 2002 99: 4357 4363
D'Sa SP, Peggs KS, Thuraisundaram D et al. CAMPATH-1H-containing nonmyeloablative allogeneic stem cell transplantation for myeloma results in delayed T cell reconstitution and a high incidence of viral infections, but low infection-related mortality Blood 2001 98: 203a (Abstr. 847)
Potter M, Grace S, Ethell M et al. High rate of CMV reactivation (but not disease) in recipient of allogeneic transplants conditioned with CAMPATH-1H Bone Marrow Transplant 2000 25: (Suppl. 1) 135
Chakrabarti S, Collingham KE, Marshall T et al. Respiratory virus infections in adult T cell-depleted transplant recipients: the role of cellular immunity Transplantation 2001 72: 1460 1463
Davison GM, Novitzky N, Kline A et al. Immune reconstitution after allogeneic bone marrow transplantation depleted of T cells Transplantation 2000 69: 1341 1347
Akashi K, Kondo M, Weissman IL . Role of interleukin-7 in T-cell development from hematopoietic stem cells Immunol Rev 1998 165: 13 28
Fry TJ, Christensen BL, Komschlies KL et al. Interleukin-7 restores immunity in athymic T-cell-depleted hosts Blood 2001 97: 1525 1533
Grigg A, Bardy P, Byron K et al. Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma Bone Marrow Transplant 1999 23: 107 110
Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy Blood 1997 89: 4531 4536
Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 1998 91: 756 763
Khouri IF, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies J Clin Oncol 1998 16: 2817 2824
Champlin R, Khouri I, Kornblau S et al. Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy Hematol Oncol Clin North Am 1999 13: 1041 1058
Carella AM, Champlin R, Slavin S et al. Mini-allografts: ongoing trials in humans (editorial) Bone Marrow Transplant 2000 25: 345 350
Nagler A, Slavin S ., Varadi G et al. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma Bone Marrow Transplant 2000 25: 1021 1028
Cull GM, Haynes AP, Byrne JL et al. Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity Br J Haematol 2000 108: 754 760
Flinn IW, Vogelsang G . Bone marrow transplantation for chronic lymphocytic leukemia Semin Oncol 1998 25: 60 64
Dreger P, von Neuhoff N, Kuse R et al. Early stem cell transplantation for chronic lymphocytic leukaemia: a chance for cure? Br J Cancer 1998 77: 2291 2297
Jindra P, Koza V, Fiser J et al. Autologous CD34+ cells transplantation after FAMP treatment in a patient with CLL and persisting AIHA: complete remission of lymphoma with control of autoimmune complications Bone Marrow Transplant 1999 24: 215 217
Itala M, Pelliniemi TT, Rajamaki A, Remes K . Autologous blood cell transplantation in B-CLL: response to chemotherapy prior to mobilization predicts the stem cell yield Bone Marrow Transplant 1997 19: 647 651
Scime R, Indovina A, Santoro A et al. PBSC mobilization, collection and positive selection in patients with chronic lymphocytic leukemia Bone Marrow Transplant 1998 22: 1159 1165
Schey S, Ahsan G, Jones R . Dose intensification and molecular responses in patients with chronic lymphocytic leukaemia: a phase II single centre study Bone Marrow Transplant 1999 24: 989 993
Dyer MJ, Kelsey SM, Mackay HJ et al. In vivo ‘purging’ of residual disease in CLL with Campath-1H Br J Haematol 1997 97: 669 672
Kennedy S, Rawstron A, Evans P et al. Campath-1H therapy in 29 patients with refractory CLL: ‘true’ complete remission is an attainable goal Blood 1999 94: (Suppl. 1) 603a (Abstr. 2683)
Michallet M, Archimbaud E, Bandini G et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry Ann Intern Med 1996 124: 311 315
Khouri IF, Keating MJ, Vriesendorp HM et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results J Clin Oncol 1994 12: 748 758
Pavletic ZS, Arrowsmith ER, Bierman PJ et al. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia Bone Marrow Transplant 2000 25: 717 722
Provan D, Bartlett-Pandite L, Zwicky C et al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation Blood 1996 88: 2228 2235
Lush RJ, Haynes AP, Byrne JL et al. Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPAH (+/−fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion Cytotherapy 2001 3: 203 210
Carrum G, Przepiorka D, Popat U et al. Submyeloablative conditioning regimens using anti-lymphocyte antibodies for allogeneic stem cell transplantation Blood 2001 98: 184a (Abstr. 775)
Rizzieri DA, Long GD, Vredenburgh JJ et al. Non-myeloablative allogeneic transplantation using T depleted matched sibling peripheral blood stem cells Blood 2001 98: 420a (Abstr. 1764)
Rizzieri DA, Long GD, Vredenburgh JJ et al. Non-myeloablative transplantation using CAMPATH 1H for T depletion of mismatched, related donor peripheral blood stem cells Blood 2001 98: 669a (Abstr. 2805)
Rabinowe SN, Soiffer RJ, Gribben JG et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia Blood 1993 82: 1366 1376
Bandini G, Michallet M, Rosti G, Tura S . Bone marrow transplantation for chronic lymphocytic leukemia Bone Marrow Transplant 1991 7: 251 253
Toze CL, Shepherd JD, Connors JM et al. Allograftingfor indolent lymphoid neoplasms Ann Oncol 1994 12: 748 758
Acknowledgements
We are grateful for the assistance of Janet Stephenson and Parthenon Medical Communications in the drafting of this review, with funding from Schering AG.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hale, G., Slavin, S., Goldman, J. et al. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?. Bone Marrow Transplant 30, 797–804 (2002). https://doi.org/10.1038/sj.bmt.1703733
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703733
Keywords
This article is cited by
-
A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation
Bone Marrow Transplantation (2008)
-
Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia
Oncogene (2007)